Evidence map›Paper›PMID 41178567›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC.

Hongyu Yuan, Ge Ge, LiQiu Liu, Sijun Hu, Miaomiao Tian, Yongzhan Nie, Zitong Zhao, Yongmei Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongyu YuanState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.
Ge GeState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.
LiQiu LiuState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.
Sijun HuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, 710032, P. R. China.
Miaomiao TianState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, 710032, P. R. China.
Yongzhan NieState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, 710032, P. R. China.
Zitong ZhaoState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.
Yongmei SongState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.ORCID https://orcid.org/0000-0002-7789-0158

Funding

CAMS Innovation Fund for Medical Sciences 2023-I2M-2-004National Key Research and Development Program of China 2022YFC3401000National Natural Science Foundation of China 82173332National Natural Science Foundation of China 82404659
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) progression is driven by androgen receptor (AR) signaling, while small nucleolar RNAs (snoRNAs), classically involved in ribosomal RNA processing, are increasingly recognized for non-classical roles in cancer. However, their function in ESCC remains unknown. This study investigates AR-regulated snoRNAs and their mechanistic contributions to ESCC pathogenesis. SNORA80B is identified as the most AR-responsive snoRNA with oncogenic activity by transcriptomic profiling. Beyond its classical role, SNORA80B stabilizes cholesterol metabolism transcripts via N⁶-methyladenosine (m

Indexed as

CholesterolCisplatinDrug Resistance, NeoplasmEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaRNA, Small NucleolarAdenosineAnimalsCell Line, TumorHumansReceptors, AndrogenSignal TransductionAdenosineCholesterolCisplatinReceptors, AndrogenRNA, Small Nucleolarandrogen receptorcholesterol metabolismesophageal squamous cell carcinomam6A modificationSNORA80B

Identifiers

PMID41178567
PMCPMC12884767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.